Cormorant Asset Management, LP, 10% Owner at Ambrx Biopharma Inc. (AMAM), bought 4,305,476 shares at $9.05 ($39.3M) on 2023-09-15, disclosed to the SEC on 2023-09-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.05 | 1,401,505 | $12.7M | 32.3% |
| 2 | $9.05 | 1,401,505 | $12.7M | 32.3% |
| 3 | $9.24 | 751,233 | $6.9M | 17.7% |
| 4 | $9.24 | 751,233 | $6.9M | 17.7% |
| Total | $9.12 avg | 4,305,476 | $39.3M | 100% |
| Filing → |
| DRUG | BUY | 2024-11-06 | $8.0M | — | Filing → |
| EYPT | BUY | 2024-05-08 | $20.2M | — | Filing → |
| CRBP | BUY | 2024-02-06 | $14.3M | — | Filing → |